Lin Qin

ORCID: 0000-0003-4159-950X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Epigenetics and DNA Methylation
  • RNA modifications and cancer
  • Genomics, phytochemicals, and oxidative stress
  • Cancer-related gene regulation
  • Lung Cancer Treatments and Mutations
  • Garlic and Onion Studies
  • Plant-derived Lignans Synthesis and Bioactivity

Capital Medical University
2023-2024

Beijing Chest Hospital
2023-2024

Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has brought significant benefits to non-small cell lung cancer (NSCLC) patients EGFR mutations.However, most eventually develop acquired resistance after treatment.This study investigated the epigenetic effects of mucin 17 (MUC17) in drug-resistant cells EGFR-TKIs.We found that GR/OR (gefitinib/osimertinib-resistance) enhance genome-wide DNA hypermethylation, mainly 5-UTR associated multiple oncogenic...

10.7150/ijbs.75963 article EN cc-by-nc International Journal of Biological Sciences 2023-01-01

Abstract Cancer is a highly heterogeneous disease that poses serious threat to human health worldwide. Despite significant advances in the diagnosis and treatment of cancer, prognosis survival rate cancer remain poor due late diagnosis, drug resistance, adverse reactions. Therefore, it very necessary study development mechanism formulate effective therapeutic interventions. As widely available bioactive substances, natural products have shown obvious anticancer potential, especially by...

10.1002/ptr.8108 article EN Phytotherapy Research 2024-01-09

As confusion mounts over RNA isoforms involved in phenotypic plasticity, aberrant CpG methylation-mediated disruption of alternative splicing is increasingly recognized as a driver intratumor heterogeneity (ITH). Protease serine 3 (PRSS3), possessing four splice variants (PRSS3-SVs; PRSS3-V1-V4), an indispensable trypsin that shows paradoxical effects on cancer development. Here, we found PRSS3 transcripts and their were divergently expressed lung cancer, exhibiting opposing functions...

10.1016/j.apsb.2023.02.015 article EN cc-by-nc-nd Acta Pharmaceutica Sinica B 2023-02-24
Coming Soon ...